选择性FLT3抑制剂gilteritinib治疗复发或难治性急性髓系白血病:一项多中心、首次人体、开放标签、1-2期研究
这项多中心、首次人体、开放标签1-2期研究纳入252例复发或难治性急性髓系白血病成人患者,每日口服gilteritinib 20-450 mg。最大耐受剂量为300 mg/日;249例可评估患者中100例(40%)获得缓解,19例(8%)完全缓解。基于活性数据,120 mg/日剂量正在3期试验中测试。
要点
- 最大耐受剂量为300 mg/日,450 mg剂量组3例中2例出现剂量限制性毒性。
- 全分析集249例中100例(40%)获得缓解,19例(8%)达完全缓解。
- 基于活性数据,gilteritinib 120 mg/日正在3期试验中测试。
核心结论
- gilteritinib具有良好的安全性特征,并在复发或难治性急性髓系白血病患者中显示出一致的FLT3抑制作用。
- 这些发现证实FLT3是治疗复发或难治性急性髓系白血病的高价值靶点;基于活性数据,gilteritinib 120 mg/日正在3期试验中测试。
研究设计与样本
- 这是一项多中心、首次人体、开放标签的1-2期试验,纳入年龄18岁及以上、对诱导治疗难治或既往治疗缓解后复发的急性髓系白血病患者。
- 患者被纳入七个剂量递增或剂量扩展队列之一,每日一次口服gilteritinib 20 mg、40 mg、80 mg、120 mg、200 mg、300 mg或450 mg。
- 队列扩展基于安全性、耐受性、相关性分析中的FLT3抑制和抗白血病活性;尽管FLT3突变不是纳入标准,但要求每个剂量水平的扩展队列中至少有10例经当地确认的FLT3突变(FLT3mut+)患者。
- 基于新出现的发现,进一步扩展了120 mg和200 mg剂量队列,仅纳入FLT3mut+患者。
- 主要终点为gilteritinib的安全性、耐受性和药代动力学;安全性分析集为所有接受至少一剂gilteritinib的患者,缓解评估在全分析集(所有接受至少一剂研究药物且治疗后至少有一个数据点的患者)中进行,药代动力学在安全性分析集中有足够血浆浓度数据以推导一个或多个药代动力学变量的亚组中评估。
主要发现
- 2013年10月15日至2015年8月27日期间,252例复发或难治性急性髓系白血病成人患者每日一次口服gilteritinib,纳入七个剂量递增(n=23)或剂量扩展(n=229)队列。
- gilteritinib耐受良好;最大耐受剂量确定为300 mg/日,因450 mg剂量递增队列纳入的3例患者中2例出现两例剂量限制性毒性(3级腹泻和3级天冬氨酸氨基转移酶升高)。
- 无论与治疗是否相关,最常见的3-4级不良事件为发热性中性粒细胞减少(97/252,39%)、贫血(61/252,24%)、血小板减少(33/252,13%)、脓毒症(28/252,11%)和肺炎(27/252,11%)。
- 常见的治疗相关不良事件为腹泻(92/252,37%)、贫血(86/252,34%)、乏力(83/252,33%)、天冬氨酸氨基转移酶升高(65/252,26%)和丙氨酸氨基转移酶升高(47/252,19%)。
- 发生率≥5%的严重不良事件为发热性中性粒细胞减少(98/252,39%;5例与治疗相关)、疾病进展(43/252,17%)、脓毒症(36/252,14%;2例与治疗相关)、肺炎(27/252,11%)、急性肾衰竭(25/252,10%;5例与治疗相关)、发热(21/252,8%;3例与治疗相关)、菌血症(14/252,6%;1例与治疗相关)和呼吸衰竭(14/252,6%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia has been limited by rapid generation of resistance mutations, particularly in codon Asp835 (D835). We aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia. METHODS: In this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia who either were refractory to induction therapy or had relapsed after achieving remission with previous treatment. Patients were enrolled into one of seven dose-escalation or dose-expansion cohorts assigned to receive once-daily doses of oral gilteritinib (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg). Cohort expansion was based on safety and tolerability, FLT3 inhibition in correlative assays, and antileukaemic activity. Although the presence of an FLT3 mutation was not an inclusion criterion, we required ten or more patients with locally confirmed FLT3 mutations (FLT3mut+) to be enrolled in expansion cohorts at each dose level. On the basis of emerging findings, we further expanded the 120 mg and 200 mg dose cohorts to include FLT3mut+ patients only. The primary endpoints were the safety, tolerability, and pharmacokinetics of gilteritinib. Safety and tolerability were assessed in the safety analysis set (all patients who received at least one dose of gilteritinib). Responses were assessed in the full analysis set (all patients who received at least one dose of study drug and who had at least one datapoint post-treatment). Pharmacokinetics were assessed in a subset of the safety analysis set for which sufficient data for concentrations of gilteritinib in plasma were available to enable derivation of one or more pharmacokinetic variables. This study is registered with ClinicalTrials.gov, number NCT02014558, and is ongoing. FINDINGS: Between Oct 15, 2013, and Aug 27, 2015, 252 adults with relapsed or refractory acute myeloid leukaemia received oral gilteritinib once daily in one of seven dose-escalation (n=23) or dose-expansion (n=229) cohorts. Gilteritinib was well tolerated; the maximum tolerated dose was established as 300 mg/day when two of three patients enrolled in the 450 mg dose-escalation cohort had two dose-limiting toxicities (grade 3 diarrhoea and grade 3 elevated aspartate aminotransferase). The most common grade 3-4 adverse events irrespective of relation to treatment were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]), thrombocytopenia (33 [13%]), sepsis (28 [11%]), and pneumonia (27 [11%]). Commonly reported treatment-related adverse events were diarrhoea (92 [37%] of 252]), anaemia (86 [34%]), fatigue (83 [33%]), elevated aspartate aminotransferase (65 [26%]), and increased alanine aminotransferase (47 [19%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to treatment), progressive disease (43 [17%]), sepsis (36 [14%]; two related to treatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyrexia (21 [8%]; three related to treatment), bacteraemia (14 [6%]; one related to treatment), and respiratory failure (14 [6%]). 95 people died in the safety analysis set, of which seven deaths were judged possibly or probably related to treatment (pulmonary embolism [200 mg/day], respiratory failure [120 mg/day], haemoptysis [80 mg/day], intracranial haemorrhage [20 mg/day], ventricular fibrillation [120 mg/day], septic shock [80 mg/day], and neutropenia [120 mg/day]). An exposure-related increase in inhibition of FLT3 phosphorylation was noted with increasing concentrations in plasma of gilteritinib. In-vivo inhibition of FLT3 phosphorylation occurred at all dose levels. At least 90% of FLT3 phosphorylation inhibition was seen by day 8 in most patients receiving a daily dose of 80 mg or higher. 100 (40%) of 249 patients in the full analysis set achieved a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46 (18%) complete remission with incomplete haematological recovery, and 25 (10%) partial remission INTERPRETATION: Gilteritinib had a favourable safety profile and showed consistent FLT3 inhibition in patients with relapsed or refractory acute myeloid leukaemia. These findings confirm that FLT3 is a high-value target for treatment of relapsed or refractory acute myeloid leukaemia; based on activity data, gilteritinib at 120 mg/day is being tested in phase 3 trials. FUNDING: Astellas Pharma, National Cancer Institute (Leukemia Specialized Program of Research Excellence grant), Associazione Italiana Ricerca sul Cancro.
引用
- Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017. PMID: 28645776. doi:10.1016/S1470-2045(17)30416-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。